{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:16:28Z","timestamp":1787904988902,"version":"build-2784847793"},"reference-count":27,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1183\/13993003.01506-2025","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:15Z","timestamp":1760028915000},"page":"2501506","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The European Medicines Agency's review of elexacaftor\/tezacaftor\/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I\n                    <i>CFTR<\/i>\n                    variants"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2659-3058","authenticated-orcid":false,"given":"Catherine","family":"Drai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke J.","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-4655","authenticated-orcid":false,"given":"Anne J.","family":"Lexmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-8020","authenticated-orcid":false,"given":"Tineke","family":"van den Hoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-3180","authenticated-orcid":false,"given":"Peter G.M.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-485X","authenticated-orcid":false,"given":"Finbarr P.","family":"Leacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Przybyszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-0955","authenticated-orcid":false,"given":"Bruno","family":"Sepodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Castelnovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026010801350632000_67.1.2501506.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2391-y"},{"key":"2026010801350632000_67.1.2501506.2","unstructured":"Zolin A , Adamoli A , Bakkeheim E . European Cystic Fibrosis Society Patient Registry Annual Report 2023. Karup, European Cystic Fibrosis Society, 2025."},{"key":"2026010801350632000_67.1.2501506.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.009"},{"key":"2026010801350632000_67.1.2501506.4","unstructured":"European Medicines Agency . Orphan Designation: Overview. Date last accessed: 31 August 2025. www.ema.europa.eu\/en\/human-regulatory-overview\/orphan-designation-overview"},{"key":"2026010801350632000_67.1.2501506.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2216474"},{"key":"2026010801350632000_67.1.2501506.6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026010801350632000_67.1.2501506.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8120"},{"key":"2026010801350632000_67.1.2501506.8","unstructured":"Cystic Fibrosis Mutation Database . Date last accessed: 27 February 2025. www.genet.sickkids.on.ca\/StatisticsPage.html"},{"key":"2026010801350632000_67.1.2501506.9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2026010801350632000_67.1.2501506.10","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E14-04-0935"},{"key":"2026010801350632000_67.1.2501506.11","unstructured":"CFTR2 . Clinical and Functional Translation of CFTR. Date last accessed: 27 February 2025. www.cftr2.org"},{"key":"2026010801350632000_67.1.2501506.12","unstructured":"European Medicines Agency . Assessment Report \u2013 Kalydeco (Ivacaftor) \u2013 Procedure Number: EMEA\/H\/C\/002494\/\/0000. London, European Medicines Agency, 2012."},{"key":"2026010801350632000_67.1.2501506.13","unstructured":"European Medicines Agency . Assessment Report \u2013 Orkambi (Lumacaftor\/Ivacaftor) \u2013 Procedure Number: EMEA\/H\/C\/003954\/0000. London, European Medicines Agency, 2015."},{"key":"2026010801350632000_67.1.2501506.14","unstructured":"European Medicines Agency . Assessment Report \u2013 Symkevi (Tezacaftor\/Ivacaftor) \u2013 Procedure Number: EMEA\/H\/C\/004682\/0000. London, European Medicines Agency, 2018."},{"key":"2026010801350632000_67.1.2501506.15","unstructured":"European Medicines Agency . Assessment Report \u2013 Kaftrio (Ivacaftor\/Tezacaftor\/Elexacaftor) \u2013 Procedure Number: EMEA\/H\/C\/005269\/0000. Amsterdam, European Medicines Agency, 2020."},{"key":"2026010801350632000_67.1.2501506.16","unstructured":"European Medicines Agency . Assessment Report \u2013 Kaftrio (Ivacaftor\/Tezacaftor\/Elexacaftor) \u2013 Procedure Number: EMEA\/H\/C\/005269\/X\/0008\/G. Amsterdam, European Medicines Agency, 2021."},{"key":"2026010801350632000_67.1.2501506.17","unstructured":"Cystic Fibrosis Foundation . Cystic Fibrosis Foundation Patient Registry 2023 Annual Data Report. Bethesda, Cystic Fibrosis Foundation, 2025."},{"key":"2026010801350632000_67.1.2501506.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.12.003"},{"key":"2026010801350632000_67.1.2501506.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2026010801350632000_67.1.2501506.20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026010801350632000_67.1.2501506.21","unstructured":"European Medicines Agency . Assessment Report \u2013 Kaftrio (ivacaftor\/tezacaftor\/elexacaftor) \u2013 Procedure Number: EMEA\/H\/C\/WS2551. Amsterdam, Cystic Fibrosis Foundation, 2025."},{"key":"2026010801350632000_67.1.2501506.22","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201708-668ps"},{"key":"2026010801350632000_67.1.2501506.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01146-2024"},{"key":"2026010801350632000_67.1.2501506.24","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-781OC"},{"key":"2026010801350632000_67.1.2501506.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"2026010801350632000_67.1.2501506.26","unstructured":"European Medicines Agency . Kaftrio \u2013 Product information. Date last accessed: 27 February 2025. www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf"},{"key":"2026010801350632000_67.1.2501506.27","unstructured":"European Medicines Agency . Kalydeco \u2013 Product information. Date last accessed: 27 February 2025. www.ema.europa.eu\/en\/documents\/product-information\/kalydeco-epar-product-information_en.pdf"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01506-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:35:17Z","timestamp":1767864917000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01506-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/13993003.01506-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01506-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}